Journal article icon

Journal article

A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial

Abstract:

Background Azithromycin is an orally active synthetic macrolide antibiotic with a wide range of anti-bacterial, anti-inflammatory and antiviral properties. It is a safe, inexpensive, generic licenced drug available worldwide and manufactured to scale and is a potential candidate therapy for pandemic coronavirus disease 2019 (COVID-19). Azithromycin was widely used to treat severe SARS-CoV and MERS-CoV, but to date, no randomised data are available in any coronavirus infect...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1186/s13063-020-04593-8

Authors


More by this author
Division:
MSD
Department:
NDM
Sub department:
NDM Experimental Medicine
Role:
Author
ORCID:
0000-0003-0699-2373
Expand authors...
Publisher:
BioMed Central Publisher's website
Journal:
Trials Journal website
Volume:
21
Article number:
718
Publication date:
2020-08-17
Acceptance date:
2020-07-07
DOI:
EISSN:
1745-6215
Language:
English
Keywords:
Pubs id:
1116923
Local pid:
pubs:1116923
Deposit date:
2020-07-07

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP